Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 5,980,000 shares, a drop of 26.1% from the February 28th total of 8,090,000 shares. Approximately 4.8% of the company’s stock are short sold. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 5.5 days.

Lyell Immunopharma Price Performance

Shares of LYEL stock opened at $0.54 on Friday. The stock has a market capitalization of $159.78 million, a price-to-earnings ratio of -0.69 and a beta of -0.41. The company’s fifty day simple moving average is $0.61 and its two-hundred day simple moving average is $0.86. Lyell Immunopharma has a 1 year low of $0.48 and a 1 year high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Equities research analysts anticipate that Lyell Immunopharma will post -0.78 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Insider Activity

In other Lyell Immunopharma news, CFO Charles W. Newton purchased 200,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the transaction, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Lynn Seely purchased 175,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 733,000 shares of company stock worth $429,550 over the last 90 days. 25.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LYEL. Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma during the 3rd quarter valued at about $52,000. Erste Asset Management GmbH bought a new position in Lyell Immunopharma during the third quarter valued at approximately $82,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Lyell Immunopharma during the third quarter worth approximately $52,000. Centiva Capital LP bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth approximately $31,000. Finally, State Street Corp boosted its stake in shares of Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after purchasing an additional 71,233 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.